Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Vec in advanced pancreatic cancer
NCT03086642Phase 1Completed
- Start
- Nov 2017
- Primary completion
- May 2021
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in pancreatic ductal adenocarcinoma (PDAC). Primary endpoint: Maximum Tolerated Dose. Started Nov 2017; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03086642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086642.